The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, May 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 2 news outlets

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 33 Mendeley

Summary News Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease

Article in Expert Review of Respiratory Medicine (December 2023)

Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD

Article in Respiratory Medicine (June 2022)

Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial

Article in Advances in Therapy (August 2021)